Effectiveness Analysis of Single Dose Rifampicin-Post-Exposure Prophylaxis (SDR-PEP) as  A Preventive Intervention for Leprosy Transmission:  A Systematic Review of Randomized Controlled Trials

Muhammad Mikail Athif Zhafir Asyura; Ilma Ranjani Wijaya; Theetouch Toshukowong; Rui Sheng Wang

doi:10.14710/jphtcr.v4i2.10794

DOI: https://doi.org/10.14710/jphtcr.v4i2.10794

Effectiveness Analysis of Single Dose Rifampicin-Post-Exposure Prophylaxis (SDR-PEP) as A Preventive Intervention for Leprosy Transmission: A Systematic Review of Randomized Controlled Trials

Muhammad Mikail Athif Zhafir Asyura¹

, Ilma Ranjani Wijaya¹, Theetouch Toshukowong², Rui Sheng Wang³

¹Faculty of Medicine, Universitas Indonesia, Depok, Jawa Barat, Indonesia

²Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

³Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Received: 8 Apr 2021; Published: 30 Aug 2021.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

BibTex Citation Data :

@article{JPHTCR10794,
    author = {Muhammad Asyura and Ilma Wijaya and Theetouch Toshukowong and Rui Wang},
    title = {Effectiveness Analysis of Single Dose Rifampicin-Post-Exposure Prophylaxis (SDR-PEP) as  A Preventive Intervention for Leprosy Transmission:  A Systematic Review of Randomized Controlled Trials},
    journal = {Journal of Public Health for Tropical and Coastal Region},
  volume = {4},
    number = {2},
    year = {2021},
    keywords = {chemoprophylaxis; leprosy; post exposure prophylaxis; single dose rifampicin},
    abstract = {  Introduction:  Leprosy is a skin disease that reaches 200,000 cases annually. Considered a neglected tropical disease, 80% of annual leprosy remained in countries such as Brazil, India, and Indonesia. Multi-drug treatment is effective in curing leprosy but ineffective in preventing further transmission. The implementation of large-scale single dose rifampicin-post exposure prophylaxis suggests the inhibition of leprosy transmission and thus needs validation.   Methods:  This systematic review was carried out based on the PRISMA statement from multiple databases using set keywords. A total of 646 studies were identified, followed by 4 randomized controlled trials included after screening.   Results : 86,502 subjects were divided into control and interventional groups and were to be followed up in 2-6 years. Most studies showed a significant decrease of leprosy cases by 50-60%. Furthermore, a complementary effect between single-dose rifampicin-post exposure prophylaxis and Bacillus Calmette–Guérin vaccine was identified. Moreover, the cost-effectiveness of the intervention was analyzed which resulted in IDR 80,414,775 being averted in its 25th year of implementation   Conclusion : The review established promising results of implementing single dose rifampicin-post exposure prophylaxis to prevent leprosy transmission. Further national scale intervention with a multi-layered approach is suggested to ensure full support and continuity of the large-scale intervention    },
   issn = {2597-4378},   pages = {35--43}  doi = {10.14710/jphtcr.v4i2.10794},
    url = {https://ejournal2.undip.ac.id/index.php/jphtr/article/view/10794}
}

Citation Format:

Abstract

Introduction: Leprosy is a skin disease that reaches 200,000 cases annually. Considered a neglected tropical disease, 80% of annual leprosy remained in countries such as Brazil, India, and Indonesia. Multi-drug treatment is effective in curing leprosy but ineffective in preventing further transmission. The implementation of large-scale single dose rifampicin-post exposure prophylaxis suggests the inhibition of leprosy transmission and thus needs validation.

Methods: This systematic review was carried out based on the PRISMA statement from multiple databases using set keywords. A total of 646 studies were identified, followed by 4 randomized controlled trials included after screening.

Results: 86,502 subjects were divided into control and interventional groups and were to be followed up in 2-6 years. Most studies showed a significant decrease of leprosy cases by 50-60%. Furthermore, a complementary effect between single-dose rifampicin-post exposure prophylaxis and Bacillus Calmette–Guérin vaccine was identified. Moreover, the cost-effectiveness of the intervention was analyzed which resulted in IDR 80,414,775 being averted in its 25th year of implementation

Conclusion: The review established promising results of implementing single dose rifampicin-post exposure prophylaxis to prevent leprosy transmission. Further national scale intervention with a multi-layered approach is suggested to ensure full support and continuity of the large-scale intervention

Note: This article has supplementary file(s).

Fulltext View|Download | Supplementary Figure

Figure 1. PRISMA Flow Chart Diagram of Search Strategies

Subject
Type	Supplementary Figure
	Download (93KB) Indexing metadata

Statement Letter

Statement Letter

Subject
Type	Statement Letter
	Download (B) Indexing metadata

Statement Letter

Statement Letter

Subject
Type	Statement Letter
	Download (99KB) Indexing metadata

Keywords: chemoprophylaxis; leprosy; post exposure prophylaxis; single dose rifampicin

Article Metrics:

Article Info

Section: Articles

Language : EN

In Vol 4, No 2 (2021): Journal of Public Health for Tropical and Coastal Region

Recent articles

Microplastic Pollution in Waters and its Impact on Health and Environment in Indonesia: A Review Effectiveness Analysis of Single Dose Rifampicin-Post-Exposure Prophylaxis (SDR-PEP) as A Preventive Intervention for Leprosy Transmission: A Systematic Review of Randomized Controlled Trials Risk of Psychiatric Problems for People with Negative Psychosocial Impacts in Compared to Positive Attitude during Covid-19 Pandemic: A Systematic Review More recent articles

Blok DJ, Vlas SJD, Richardus JH. Global elimination of leprosy by 2020: are we on track? Parasites and Vectors. 2015;8:548
Bennet BH, Parker DL, Robson M. Leprosy: steps along the journey of eradication. Public Health Rep. 2008;123(2):198–205
World Health Organization. Integrating neglected tropical diseases into global health and development: fourth WHO report on neglected tropical diseases. Geneva: World Health Organization; 2013
United Nations. The 17 goals. New York: United Nations; 2020. Available from: https://sdgs.un.org/goals. Accessed 9 Dec 2020
Cochrane. RoB 2: A revised Cochrane risk-of-bias tool for randomized trials. London: Cochrane; date unknown. Available from: https://methods.cochrane.org/bias/resources/rob-2-revised-cochrane-risk-bias-tool-randomized-trials
Moet FJ, Pahan D, Oskam L, Richardus JH; COLEP Study Group. Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. BMJ. 2008;336(7647):761-4
Richardus R, Alam K, Kundu K, Chandra Roy J, Zafar T, Chowdhury AS, Nieboer D, Faber R, Butlin CR, Geluk A, Richardus J, et al. Effectiveness of single-dose rifampicin after BCG vaccination to prevent leprosy in close contacts of patients with newly diagnosed leprosy: A cluster randomized controlled trial. Int J Infect Dis. 2019;88:65-72
Feenstra SG, Pahan D, Moet FJ, Oskam L, Richardus JH. Patient-related factors predicting the effectiveness of rifampicin chemoprophylaxis in contacts: 6 year follow up of the COLEP cohort in Bangladesh. Lepr Rev. 2012; 83(3): 292-304
Schuring RP, Richardus JH, Pahan D, Oskam L. Protective effect of the combination BCG vaccination and rifampicin prophylaxis in leprosy prevention. Vaccine. 2009;27(50): 7125-8. Available from: https://pubmed.ncbi.nlm.nih.gov/19786134/
Malathi M, Thappa DM. Fixed-duration therapy in leprosy: limitations and opportunities. Indian J Dermatol. 2013;58(2):93-100
Mieras LF, Taal AT, van Brakel WH, Cambau E, Saunderson PR, Smith WCS, et al. An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP+. BMC Infect Dis. 2018;18(1):506
Cambau E, Williams DL. Anti-Leprosy Drugs: Modes of Action and Mechanisms of Resistance in Mycobacterium leprae. International USA: Textbook of Leprosy. Available from: https://internationaltextbookofleprosy.org/chapter/anti-leprosy-drugs-modes-action-and-mechanisms-resistance-mycobacterium-leprae. Accessed 15 Dec 2020
Schoenmakers A, Mieras L, Budiawan T, van Brakel WH. The State of Affairs in Post-Exposure Leprosy Prevention: A Descriptive Meta-Analysis on Immuno- and Chemo-Prophylaxis. Res Rep Trop Med. 2020;11:97-117. doi: 10.2147/RRTM.S190300
Tiwari A, Blok DJ, Arif M, Richardus JH. Leprosy post-exposure prophylaxis in the Indian health system: A cost-effectiveness analysis. PLoS Negl Trop Dis. 2020;14(8):e0008521
Schoenmakers, Anne; Mieras, Liesbeth; Budiawan, Teky; van Brakel, Wim H. Research and reports in tropical medicine. Macclesfield. 2020; 97-117
Netherland Leprosy Relief. NLR Indonesia. Amsterdam: NLR. Available from: https://nlrinternational.org/what-we-do/indonesia/. Accessed 22 June 2021
Amelia N. Indonesia still ranked third with leprosy, UNAIR expert: We are all responsible for leprosy elimination. Surabaya: Universitas Airlangga. Available from: http://news.unair.ac.id/en/2020/01/29/indonesia-still-ranked-third-with-leprosy-unair-expert-we-are-all-responsible-for-leprosy-elimination. Accessed 22 June 2021

Last update:

No citation recorded.

Last update:

No citation recorded.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Starting in 2021, the author(s) whose article is published in the JPHTCR journal attain the copyright for their article. By submitting the manuscript to JPHTCR, the author(s) agree with this policy. No special document approval is required.

The author(s) guarantee that their article is original, written by the mentioned author(s), has never been published before, does not contain statements that violate the law, does not violate the rights of others, is subject to copyright that is held exclusively by the author(s), and is free from the rights of third parties, and that the necessary written permission to quote from other sources has been obtained by the author(s).

The author(s) retain all rights to the published work, such as (but not limited to) the following rights:

Copyright and other proprietary rights related to articles, such as patents,
The right to use the substance of the article in its own future works, including lectures and books,
The right to reproduce articles for its own purposes,
The right to archive articles yourself (please read our deposit policy), and
The right to enter into separate additional contractual arrangements for the non-exclusive distribution of published versions of articles (for example, posting them to institutional repositories or publishing them in a book), with acknowledgment of its initial publication in this journal (Journal of Public Health for Tropical and Coastal Region).
If the article was prepared jointly by more than one author, each author submitting the manuscript warrants that they have been given permission by all co-authors to agree to copyright and license notices (agreements) on their behalf, and agree to notify the co-authors of the terms of this policy. JPHTCR will not be held responsible for anything that may arise because of the writer's internal dispute. JPHTCR will only communicate with correspondence authors.

Authors should also understand that once published, their articles (and any additional files, including data sets, and analysis/computation data) will become publicly available. The license of published articles (and additional data) will be governed by the Creative Commons Attribution license as currently featured on the Creative Commons Attribution-ShareAlike 4.0 International License. JPHTCR allows users to copy, distribute, display and perform work under license. Users need to attribute the author(s) and JPHTCR to distribute works in journals and other publication media. Unless otherwise stated, the author(s) is a public entity as soon as the article is published.